论文部分内容阅读
目的探讨TACE联合阿德福韦酯或拉米夫定对原发性肝癌患者肝功能的改善作用。方法回顾性分析2011年2月至2013年2月我院收治的75例原发性肝癌患者的临床资料。结果 A、B、C组患者治疗的总有效率分别为84%、80%、64%,A、B组患者治疗的总有效率明显比C组高(P<0.05),但A、B两组患者治疗的总有效率相比差异不显著(P>0.05)。结论 TACE联合阿德福韦酯或拉米夫定较单纯TACE对原发性肝癌患者肝功能的改善作用明显,值得推广。
Objective To investigate the effect of TACE combined with adefovir dipivoxil or lamivudine on liver function in patients with primary liver cancer. Methods The clinical data of 75 patients with primary liver cancer admitted to our hospital from February 2011 to February 2013 were retrospectively analyzed. Results The total effective rates of treatment in group A, B and C were 84%, 80% and 64% respectively. The total effective rate of treatment in group A and B was significantly higher than that in group C (P <0.05) The total effective rate of treatment group was no significant difference (P> 0.05). Conclusion TACE combined with adefovir dipivoxil or lamivudine than pure TACE on the improvement of liver function in patients with primary liver cancer obvious role, it is worth promoting.